Salem, NH, January 26, 2016 --(PR.com
)-- ALPCO recently launched a new panel of 13 stool-based gastroenterology assays
that are all compatible with one single extraction step. The unique extraction method allows laboratories to improve their sample processing time by up to 86% by extracting one sample for up to 13 biomarkers. In addition, each of these assays is flexible and can be run manually or on automated open platforms.
“We understand the challenges facing lab managers and directors who need to continuously improve workflow efficiency and implement new tests and technologies to be competitive,” explains ALPCO’s president, Sean Conley. “Our distinctive extraction method coupled with this new gastroenterology portfolio will assist labs in achieving these objectives, while also saving time and money.”
This panel of 13 compatible gastroenterology assays consists of various biomarkers to aid in the investigation of IBD, exocrine pancreatic function, food intolerance, and colorectal cancer including calprotectin, albumin, alpha-1 antitrypsin, beta defensin 2, bile acids, lysozyme, secretory IgA, pancreatic elastase, EDN/EPX, anti-gliadin and anti-transglutaminase antibodies, as well as hemoglobin and hemo/haptoglobin complex.
To learn more, contact Jennifer Mayes
, Vice President of Sales and Commercial Development.
American Laboratory Products Company (ALPCO) was founded in 1991 as an importer and distributor of immunoassay-based products for the North American life science markets. The company has since grown into a premier channel representing over 60 collaborating partners from around the globe. In 2008, ALPCO expanded its capabilities with the launch of an organically developed product line focused in the area of diabetes and obesity research while also remaining true to its roots by continuing to provide “Immunoassays Beyond the Ordinary.” www.alpco.com